北京医学
北京醫學
북경의학
BEIJING MEDICAL JOURNAL
2015年
2期
197-199
,共3页
血脂代谢异常%心脑宁胶囊%痰浊阻遏证%脾虚湿盛证%气滞血瘀证
血脂代謝異常%心腦寧膠囊%痰濁阻遏證%脾虛濕盛證%氣滯血瘀證
혈지대사이상%심뇌저효낭%담탁조알증%비허습성증%기체혈어증
Dyslipidemia Xinnaoning capsule%Phlegm-turbidity accumulation type%Spleen deficiency syndrome type%Qi stagnation and blood stasis type
目的：观察心脑宁胶囊治疗血脂代谢异常的临床疗效及安全性。方法将86例血脂代谢异常的患者随机分为治疗组（44例）和对照组（42例）。两组均予相同的基础治疗，对照组加用辛伐他汀（40 mg，晚间服），治疗组加用心脑宁胶囊（每次3粒，每日3次），1个疗程均为12周，观察记录治疗前后血脂指标及症状积分的变化。结果治疗组总有效率为88.6%，显著高于对照组（69.0%，掊2=6.58，P<0.01）。治疗后治疗组TC、TG、LDL-C的降低程度显著优于对照组，HDL-C升高程度显著优于对照组，差异均有统计学意义（P<0.05）。治疗组症状积分改善情况优于对照组（掊2=9.89，P<0.01）。治疗组未出现毒副反应。结论心脑宁胶囊改善血脂代谢指标疗效显著、安全可靠，且能更好地减轻临床症状。
目的：觀察心腦寧膠囊治療血脂代謝異常的臨床療效及安全性。方法將86例血脂代謝異常的患者隨機分為治療組（44例）和對照組（42例）。兩組均予相同的基礎治療，對照組加用辛伐他汀（40 mg，晚間服），治療組加用心腦寧膠囊（每次3粒，每日3次），1箇療程均為12週，觀察記錄治療前後血脂指標及癥狀積分的變化。結果治療組總有效率為88.6%，顯著高于對照組（69.0%，掊2=6.58，P<0.01）。治療後治療組TC、TG、LDL-C的降低程度顯著優于對照組，HDL-C升高程度顯著優于對照組，差異均有統計學意義（P<0.05）。治療組癥狀積分改善情況優于對照組（掊2=9.89，P<0.01）。治療組未齣現毒副反應。結論心腦寧膠囊改善血脂代謝指標療效顯著、安全可靠，且能更好地減輕臨床癥狀。
목적：관찰심뇌저효낭치료혈지대사이상적림상료효급안전성。방법장86례혈지대사이상적환자수궤분위치료조（44례）화대조조（42례）。량조균여상동적기출치료，대조조가용신벌타정（40 mg，만간복），치료조가용심뇌저효낭（매차3립，매일3차），1개료정균위12주，관찰기록치료전후혈지지표급증상적분적변화。결과치료조총유효솔위88.6%，현저고우대조조（69.0%，부2=6.58，P<0.01）。치료후치료조TC、TG、LDL-C적강저정도현저우우대조조，HDL-C승고정도현저우우대조조，차이균유통계학의의（P<0.05）。치료조증상적분개선정황우우대조조（부2=9.89，P<0.01）。치료조미출현독부반응。결론심뇌저효낭개선혈지대사지표료효현저、안전가고，차능경호지감경림상증상。
Objective To observe the safety and efficacy of Xinnaoning capsule in the treatment of dyslipidemia. Methods Eight-six patients with dyslipidemia were randomly divided into the Xinnaoning group (44 cases) and Simvas-tatin group (42 cases), the treatment course was 12 weeks. The levels of total cholesterol (TC), triglyceride (TG), high den-sity lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), C-reaction protein (CRP), symptom score and safety index before and after the treatment were detected. Results After 12 weeks treatment, the total effective rate of the Xinnaoning group was 88.6%, the level of TG, CRP and symptom score was decreased and the level of HDL-C was increased, the difference was significant when compared with Simvastatin group (P< 0.05). There was no significant difference in the safety index between Xinnaoning group and Simvastatin group. Conclusion Xinnaoning capsule can regulate serum lipid level effectively and safely and improve the quality of life of patients.
